In Europe, Japan and New Zealand
Suven Life Sciences announced the grant of one (1) process patent from Europe (3077375), one (1) process patent from Japan (6151453) and one (1) process patent from New Zealand (719671) corresponding to the New Chemical Entities (NCEs) which are for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034.These process patents are for the Company's pipeline compounds which are in the class of selective 5-HT6 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
